|
KMID : 1148920160500010038
|
|
Nuclear Medicine and Molecular Imaging
2016 Volume.50 No. 1 p.38 ~ p.45
|
|
|
Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma
|
|
Lee Suk-Hyun
Han Sang-Won
Lee Hyo-Sang
Chae Sun-Young
Lee Jong-Jin
Song Dong-Eun
Ryu Jin-Sook
|
|
|
Abstract
|
|
|
Purpose: The BRAF mutation, a potential prognostic factor in papillary thyroid carcinoma (PTC), is associated with a high expression of the glucose transporter gene. We investigated which clinicopathologic factors, including BRAF mutation status, influence 18F-fluoro-2-deoxyglucose (18F-FDG) avidity.
Methods: We retrospectively reviewed 55 patients who underwent BRAF analysis from biopsy-confirmed PTC and 18F-FDG positron emission tomography/computed tomography within 6 months before undergoing thyroid surgery from September 2008 to August 2014. Tumors were considered to be 18F-FDG avid if the uptake was greater than that of the liver. 18F-FDG uptake of PTCs was also analyzed semiquantitatively using SUVmax. The association between 18F-FDG avidity and clinicopathologic variables (age, tumor size, perithyroidal extension, cervical lymph node status, and BRAF mutation status) was investigated.
Results: Twenty-nine (52.7 %) of 55 patients had 18F-FDG-avid PTCs. PTCs with the BRAF mutation showed higher 18F-FDG avidity (24/38, 63.2 %) than those without (5/17, 29.4 %). The BRAF mutation (p?=?0.025) and tumor size (p?=?0.003) were significantly associated with 18F-FDG avidity in univariate analysis, and the BRAF mutation status remained significant after adjusting for tumor size in multivariate analysis (p?=?0.015). In the subgroup of tumor size?≥?1 cm, the BRAF mutation was the only factor significantly associated with 18F-FDG avidity (p?=?0.021). The mean SUVmax of PTCs with the BRAF mutation was significantly higher than that of those without (4.89?±?6.12 vs. 1.96?±?1.10, p?=?0.039).
Conclusions: The BRAF mutation must be one of the most important factors influencing 18F-FDG avidity in PTCs, especially in those with a tumor size?≥?1 cm.
|
|
|
KEYWORD
|
|
|
18F-fluorodeoxyglucose, Positron-emission tomography, BRAF mutation, Papillary thyroid carcinoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|